Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.51 |
| ▸ | DRD4 | P21917 | 7/20 | 0.51 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3795002 | 0.98 | DRD3 (0.50) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL29535086 | 0.85 | DRD3 (0.54) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL23587071 | 0.82 | DRD3 (0.55) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL6610807 | 0.81 | DRD3 (0.57) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL20653885 | 0.78 | DRD3 (0.51) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL25297439 | 0.78 | DRD3 (0.51) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL16050082 | 0.78 | DRD3 (0.54) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL9610941 | 0.78 | DRD3 (0.58) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL22792160 | 0.78 | DRD3 (0.54) | DRD3DRD4EPHB3DRD2HTR1A | |
| SCHEMBL6612386 | 0.78 | DRD3 (0.54) | DRD3DRD4EPHB3DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | claimed |
| US-20250059184-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023114844-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114844-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059184-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GAP43, GRIN2C | DRD3 225/4885DRD4 187/4885EPHB3 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.